We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.66% | 7.65 | 7.60 | 7.70 | 7.70 | 7.65 | 7.70 | 64,978 | 08:19:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -3.93M | -0.0079 | -9.68 | 38M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/7/2024 17:19 | I wonder after today's news will Poolbeg be looking for new premises. Friel cannot remain Chairman of Hvivo and he's the only tie between the 2 entities after the spinout | chica1 | |
22/7/2024 07:33 | Should come down cheesy this week;)) | baldrick1 | |
16/7/2024 15:11 | Like a Mcdonald whopper??? ;)) | baldrick1 | |
15/7/2024 14:13 | That was a whopper of a trade. | chica1 | |
15/7/2024 07:41 | 12.50p-13p a very interesting target. | baldrick1 | |
10/7/2024 10:03 | peterrr3 they have found interesting targets with the AI tool and are looking into them, all part of the pipeline. I personally would be very surprised if they didnt considering the quality of the database they are mining. | pogue | |
10/7/2024 09:16 | The patent office reckon they have nothing unique with their AI prediction algorithm, but let's hope that doesn't stop them finding something useful with it, just means they don't have anything to license off the AI tools. | peterrr3 | |
10/7/2024 09:15 | Did he pay 11p, same as the chairman?? | baldrick1 | |
10/7/2024 08:00 | Looks like Michael Kelly has increased his holding to about £3.5m That shows confidence. John | 2350220 | |
09/7/2024 16:30 | Nasdaq eventually. Sounded a little further off than Christmas | inaminute | |
09/7/2024 15:51 | Are we all 'VERY EXCITED'. Let's hope the AI program kicks off because Hvivo will be the largest benefactor. | chica1 | |
09/7/2024 06:12 | Zak catches up with #POLB https://www.share-ta | burtond1 | |
08/7/2024 06:59 | Great to see #POLB in the Times https://www.thetimes | burtond1 | |
04/7/2024 08:15 | Nice profit there;) | baldrick1 | |
04/7/2024 07:23 | Witty to sell at this level. | baldrick1 | |
03/7/2024 09:02 | 🥱 🥱 | chica1 | |
03/7/2024 07:01 | If that counts as witty where you are from I guess we cannot expect more | inaminute | |
02/7/2024 18:01 | U just did man so I guess it applies to u.. Don't you know they're 2 words! Why can't the English teach their children how to speak??😔 | chica1 | |
02/7/2024 17:10 | Anybody who uses alot has a big moron sign on their forehead | inaminute | |
02/7/2024 14:50 | Absolutely right Peter,Pogue like most of the morons on here don't like to see the other side of the coin. The U-turn on POLB001 sent it back to Pre-Clinical. Long long road and alotta more pigs at the trough to feed with the hires late last year. Only bet what you can afford to lose!!! | chica1 | |
02/7/2024 12:04 | OK no worries you seem a normal poster. Time will indeed tell. | pogue | |
02/7/2024 11:48 | No problem Pogue we'll just agree to disagree on this one. Will know before too long who called it right. I hold plenty so I expect some upside either way it plays out. | peterrr3 | |
02/7/2024 11:38 | peterr3 I will spell it out as I feel you were listening to the wrong bits there. The lead asset of POLB is POLB001 and will be the first monetized. 2 pharmas are interested in it as their new very powerful cancer drugs have the side effect of cytokine storms. Cytokline storms mean that patients tie up hospital beds in cancer units thus reducing the amount of drugs that can be administered so huge incentive to find a drug that prevents them happening, like POLB001. Hugh incentive there for a phamra to partner with POLB if POLB001 works. Now as a stand alone drug POLB001 does the job all they have to do is prove it works whilst other drugs are in a patients system. The 2 pharmas have already given POLB the drugs, worth £millions, to run the trial and will pay for the trial as the market for their drug is 10s of $billions. We await the trial date how long do you think the pharmas are going to wait with a prize of that size? Now the other part you need to research is what normally happens in these situations ie a drug going to trial with another and what the trial contract normally says baring in mind that if it proves successful the value of POLB001 goes through the roof. Clue the contract has a section on that and I strongly suggest that is the reason for the delay as its a very important section.. Sorry if very direct but you have missed the point completely of what is happening and this board has so many halfwit derampers who avoid basic facts that I treat posters I dont know with suspicion. | pogue | |
02/7/2024 09:51 | Pogue we must be listening to different presentations because you don't really need to read between the lines to understand the carefully chosen words and they are very carefully chosen. The example he provides of using an income producing asset to fund the pipeline was a clear short to medium time plan. The mention they almost bought into something not long ago but it didn't stack up. The repeated mention of more orphan drugs, which POLB ain't is the main focus. There's simply not enough money to do much with the current pipeline. | peterrr3 | |
01/7/2024 20:54 | Pogue you use alot of words to say absolutely nothing.You honestly believe everything management of a company tells you. Tell that to the sunken shareholders of Deepverge/Modern Water who were conned by their Ex CEO Gerald Brandon. That being said I think Jeremy is a decent bloke and it's the only reason I'll retain half my distribution. | chica1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions